Clinical Trial Update: A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1, open-label, multicenter dose-escalation study of IBI363 (PD1-IL2m) in adults with advanced solid tumors or lymphomas; trial status is active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• IBI363

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Solid Malignancies or Lymphomas | Phase 1 | Status: ACTIVE_NOT_RECRUITING